RNA Interference (RNAi) Drug Delivery Market Trends, Share, Driving Factors, Opportunity and Forecast 2022-2027

According to IMARC Group's latest report, titled "RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", the global RNA interference (RNAi) drug delivery market reached a value of US$ 54.74 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 184.98 Billion by 2027, exhibiting at a CAGR of 22.5% during 2022-2027.

RNA interference (RNAi) drug delivery is a fundamental cellular mechanism that studies gene functions in eukaryotic organisms. It is also essential for silencing gene expressions for the development of new drugs. RNAi is considered a potential approach for treating various pathologic conditions, including cardiovascular diseases (CVDs), viral infections and cancer. It includes nonviral delivery of siRNA and viral delivery of shRNA that is used across various preclinical models and molecular targets for its transformational effect on modern medicine.

Request for a PDF sample of this report: https://www.imarcgroup.com/rna-interference-drug-delivery-market/requestsample

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

RNA Interference (RNAi) Drug Delivery Market Trends:

The global RNA interference (RNAi) drug delivery market is primarily driven by the increasing number of academic research institutes performing RNA therapeutic studies. The rising prevalence of chronic diseases, such as cardiac defects and cancer, is also propelling the growth of the market. In recent years, the demand for RNAi has escalated due to its high level of specificity, minor side effects, and ease of synthesis. Besides this, siRNA or microRNAs (miRNA) helps in developing personalized medicines and identifying altered cellular molecules and metabolites. Furthermore, advancements in the field of nanotechnology that facilitate nanoparticle drug delivery and the overall improvements in the healthcare infrastructure are expected to provide a positive impact on the market.

RNA Interference (RNAi) Drug Delivery Market 2022-2027 Competitive Analysis and Segmentation:

Competitive Landscape with Key Players:

The competitive landscape of the global RNA interference (RNAi) drug delivery market has also been examined along with the profiles of the key players.

Some of these key players include:

Alnylam Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
Silence Therapeutics Plc
Sirnaomics Inc.

Key Market Segmentation:

The report has segmented the RNA interference (RNAi) drug delivery market based on application, technology, and region.

Breakup by Application:
Infectious Disease
Cardiology
Oncology
Neurology
Ophthalmology
Urology
Metabolic Disorders
Others

Breakup by Technology:
Nanoparticle Drug Delivery
Pulmonary Drug Delivery
Nucleic Acid Drug Delivery
Aptamer Drug Delivery

Breakup by Region:
North America (United States, Canada)
Europe (Germany, France, United Kingdom, Italy, Spain, Others)
Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, South Africa, Others)

Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=2758&flag=C

Key highlights of the report:

Market Performance (2016-2021)
Market Outlook (2022-2027)
Market Trends
Market Drivers and Success Factors
Impact of COVID-19
Value Chain Analysis
Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Related Reports by IMARC Group:

Multiple Sclerosis Therapies Market: https://bit.ly/3rzqFXH

Portable Medical Ventilators Market: https://bit.ly/3EgRNCq

Nucleic Acid Labelling Market: https://bit.ly/3V4i4Kb

Latin America Generic Drug Market: https://bit.ly/3T0mI9Z

North Africa Generic Drug Market: https://bit.ly/3SGXVIs

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.